Literature DB >> 22446345

Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.

Roberto L Muller1, Joseph C Presti, William J Aronson, Martha K Terris, Christopher J Kane, Christopher L Amling, Stephen J Freedland.   

Abstract

OBJECTIVE: To investigate whether salvage radiation therapy (SRT) may promote prostate cancer (PCa) transformation to more aggressive phenotypes. To accomplish that, we identified men who underwent SRT after radical prostatectomy for PCa and failed SRT. PSA doubling time (PSADT) was used as a surrogate endpoint for cancer aggressiveness. We compared PSADT calculated before start of SRT and after SRT failure.
METHODS: Of 287 men in the SEARCH database since 1988 who underwent SRT, we detected 78 with SRT failure defined as PSA ≥ 0.2 ng/mL above the post-SRT nadir. Of these, 39 had PSADT available before and after SRT, which was compared using Wilcoxon's paired test with men serving as their own controls. We tested predictors of PSADT change using multivariable logistic regression.
RESULTS: There were no differences in PSADT before and after SRT (10.2 vs 12.6 months; P = .46). However, in some individual cases, large changes were observed. Only seminal vesicle invasion showed a trend towards an association with a shorter post-SRT PSADT relative to the pre-SRT PSADT (P = .13).
CONCLUSION: Overall, the PSADT after and before SRT were statistically identical, suggesting that after SRT failure, PCa does not emerge with more aggressive biological features. Further studies are needed to identify predictors and the clinical relevance of individual PSADT changes noted in our study.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446345      PMCID: PMC3431014          DOI: 10.1016/j.urology.2012.01.034

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  30 in total

1.  Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis.

Authors:  S P Elliott; T J Wilt; K M Kuntz
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-06-21       Impact factor: 5.554

2.  Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data.

Authors:  M E Stokes; L Black; A Benedict; C G Roehrborn; P Albertsen
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-03-09       Impact factor: 5.554

3.  Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.

Authors:  C Catton; M Gospodarowicz; P Warde; T Panzarella; P Catton; M McLean; M Milosevic
Journal:  Radiother Oncol       Date:  2001-04       Impact factor: 6.280

4.  Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy.

Authors:  A K Leventis; S F Shariat; M W Kattan; E B Butler; T M Wheeler; K M Slawin
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

5.  Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.

Authors:  Gustavo F Carvalhal; Saima N Daudi; Donghui Kan; Dana Mondo; Kimberly A Roehl; Stacy Loeb; William J Catalona
Journal:  Urology       Date:  2010-09-16       Impact factor: 2.649

6.  Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group.

Authors:  Anna E Teeter; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2010-12-08       Impact factor: 2.649

7.  Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Leon Sun; W Robert Lee; Vladimir Mouraviev; Cary N Robertson; Philip J Walther; Thomas J Polascik; David M Albala; Judd W Moul
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

8.  The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

Authors:  Emmanuel S Antonarakis; Zhaoyong Feng; Bruce J Trock; Elizabeth B Humphreys; Michael A Carducci; Alan W Partin; Patrick C Walsh; Mario A Eisenberger
Journal:  BJU Int       Date:  2011-07-20       Impact factor: 5.588

9.  Salvage radiation in men after prostate-specific antigen failure and the risk of death.

Authors:  Shane E Cotter; Ming Hui Chen; Judd W Moul; W Robert Lee; Bridget F Koontz; Mitchell S Anscher; Cary N Robertson; Philip J Walther; Thomas J Polascik; Anthony V D'Amico
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

10.  Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Authors:  Daniel M Moreira; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.